GLP-1 RAs improve insulin signaling in neurons, which is especially relevant as insulin resistance is increasingly accepted as a shared pathological feature of both Alzheimer’s disease and Parkinson’s disease, with some researchers even referring to AD as “type 3 diabetes” [18,125]. Here, INS is linked to early-onset autosomal dominant Alzheimer disease.